Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Skip To Voice Support Menu
For Body
For Menu
For Local Menu

Home > Investor Relations

1Q Results - Fiscal Year 2013 (January-March, 2013) Conference Call

Apr 25, 2013

Apr 30: Updated Directors & Officers
Apr 25: Results for First Quarter of Fiscal Year 2013 (January - March, 2013)
Apr 25: 1Q Results (Jan 13 - Mar 13) Conference Call
Apr 18: Events & Presentations has been updated with the time of the Financial Results
Apr 01: Updated Directors & Officers

More

Jun 14

Anti-Cancer Agent “Avastin®,"
Obtained Approval for Additional Indication and
Dosage and Administration of Malignant Glioma

[

PDF 182KB]

Jun 14

Anti-Cancer Agent “Tarceva®,”
Obtained Approval for Additional Indication (First Line Therapy) of
Non-Small Cell Lung Cancer with EGFR Mutations

[

PDF 214KB]

Jun 14

Anti-Cancer Agent, Herceptin®
Obtained Approval for Dosage and Administration for
Postoperative Adjuvant Chemotherapy in Breast Cancer

[

PDF 173KB]

Jun 13

Roche’s RoACTEMRA Shows Long-Term Efficacy
in Monotherapy and also Benefits in Early Rheumatoid Arthritis

[

PDF 246KB]

Jun 10

Roche’s RoACTEMRA Approved in EU
to Treat Children with Rare Form of Arthritis

[

PDF 258KB]

More

Events & Presentations

TSE Code:4519

Chart

Annual Report 2012
(Integrated Edition
Including CSR Report)
[ 7.4MB]